Industry: Life Sciences Region: Sweden Deal Price: $1 million Deal Method: Equity investment
Company Profile:
The Swedish company was established in 2013. Its main business is to develop various types of inhalation products. Its product portfolio covers the full range of inhalation products including inhalers and dry powder preparations.
The company's business model is the patent licensing model:
The company bears the full cost and risk of developing the inhaler platform and seeks patent protection for its unique design.
The company can develop complete inhaler products according to customer requirements and, upon successful development, make technical profits by granting exclusive rights and selling royalties on the combination of substance inhalers.
The company also develops ready-to-use inhalation products, including inhaler devices and dry powder formulations, for generic drug companies and pharmaceutical companies.
The company was awarded the MedTech Outlook Award for best Drug delivery Device solution.
Cooperation Intention:
The company hopes to find strategic partners in the Chinese market to jointly develop the Chinese market.